-
Teva Pharmaceuticals USA Inc. et al v. Synthon Pharmaceuticals, Inc. et al DC CAFC
- 1:14-cv-01419
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 11/18/2014
- Closed: 01/31/2017
- Latest Docket Entry: 01/31/2017
- PACER
- Docket updated daily
4
Plaintiffs
4
Defendants
1
Accused
Product
2
Patents-in-Suit
806
Days in
Litigation
-
Teva Pharmaceuticals USA Inc. et al v. Synthon Pharmaceuticals, Inc. et al DC CAFC
- 1:14-cv-01419
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 11/18/2014
- Closed: 01/31/2017
- Latest Docket Entry: 01/31/2017
- PACER
- Docket updated daily
Cause of Action
Willful Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of
view more
|
Invalid (103)
Entry 11 |
5 |
The method of claim 1, wherein alleviating a symptom comprises reducing brain atrophy in the patient.
|
Invalid (103)
Entry 11 |
13 |
The method of claim 1, wherein the patient has not received glatiramer acetate therapy prior to initiation of the regimen.
|
Invalid (103)
Entry 11 |
14 |
The method of claim 1, wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20 mg glatiramer acetate.
|
Invalid (103)
Entry 11 |
15 |
A method of increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically
view more
|
Invalid (103)
Entry 11 |
16 |
The method of claim 15, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction.
|
Invalid (103)
Entry 11 |
17 |
The method of claim 15, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an injection site reaction.
|
Invalid (103)
Entry 11 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of reducing the frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and has MRI features consistent with multiple sclerosis comprising
view more
|
Invalid (103)
Entry 11 |
7 |
The method of claim 1, wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20 mg glatiramer acetate.
|
Invalid (103)
Entry 11 |
15 |
The method of claim 14, wherein, the lesion is a demyelinating white matter lesion visible on brain MRI and wherein the white matter lesion is at least 3 mm in diameter.
|
Invalid (103)
Entry 11 |
20 |
A method of reducing the frequency of relapses in a human patient who has experienced a first clinical episode and has MRI features consistent with multiple sclerosis comprising administering to the human patient a therapeutically effective dosage
view more
|
Invalid (103)
Entry 11 |